December I 2025

Over 200 oncologists voted on their preferred treatment in second- and third-line relapsed/refractory chronic lymphocytic leukemia.

During a live event, Claudine Isaacs, MD, discussed using elacestrant for hormone receptor–positive, HER2-low metastatic breast cancer.

During a live event, Claudine Isaacs, MD, and participants discuss using elacestrant or T-DXd after progression in ESR1-mutated metastatic breast cancer.

During a live event, Ann F. Mohrbacher, MD, discussed outcomes from the latest follow-up of the ZUMA-7 and TRANSFORM trials.

During a live event, Adriana Rossi, MD, discussed how cilta-cel induces responses and overcomes high-risk genetics in relapsed multiple myeloma.

During a live event, Ann F. Mohrbacher, MD, reviewed treatment options for a patient with early relapsed diffuse large B-cell lymphoma.

During a live event, Adriana Rossi, MD, discussed easing CAR T-cell therapy access and highlighted cilta-cel's efficacy in earlier-line myeloma.

During a live event, Christopher J. Ferreri, MD, discussed early- and late-presenting adverse events associated with talquetamab in relapsed/refractory multiple myeloma